Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Atazanavir | Hydrotalcite can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Hydrotalcite can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Hydrotalcite. |
| Dabigatran etexilate | Hydrotalcite can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Hydrotalcite can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Hydrotalcite can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Hydrotalcite can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Hydrotalcite can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Hydrotalcite can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Hydrotalcite can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Hydrotalcite can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | Hydrotalcite can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Pazopanib | Hydrotalcite can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Hydrotalcite can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcitriol | The serum concentration of Hydrotalcite can be increased when it is combined with Calcitriol. |
| Calcifediol | The serum concentration of Hydrotalcite can be increased when it is combined with Calcifediol. |
| Ergocalciferol | The serum concentration of Hydrotalcite can be increased when it is combined with Ergocalciferol. |
| Cholecalciferol | The serum concentration of Hydrotalcite can be increased when it is combined with Cholecalciferol. |
| Paricalcitol | The serum concentration of Hydrotalcite can be increased when it is combined with Paricalcitol. |
| Dihydrotachysterol | The serum concentration of Hydrotalcite can be increased when it is combined with Dihydrotachysterol. |
| Alfacalcidol | The serum concentration of Hydrotalcite can be increased when it is combined with Alfacalcidol. |
| Seocalcitol | The serum concentration of Hydrotalcite can be increased when it is combined with Seocalcitol. |
| Inecalcitol | The serum concentration of Hydrotalcite can be increased when it is combined with Inecalcitol. |
| Becocalcidiol | The serum concentration of Hydrotalcite can be increased when it is combined with Becocalcidiol. |
| Eldecalcitol | The serum concentration of Hydrotalcite can be increased when it is combined with Eldecalcitol. |
| 1alpha,24S-Dihydroxyvitamin D2 | The serum concentration of Hydrotalcite can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2. |
| Elocalcitol | The serum concentration of Hydrotalcite can be increased when it is combined with Elocalcitol. |
| Maxacalcitol | The serum concentration of Hydrotalcite can be increased when it is combined with Maxacalcitol. |
| Doxercalciferol | The serum concentration of Hydrotalcite can be increased when it is combined with Doxercalciferol. |
| Vitamin D | The serum concentration of Hydrotalcite can be increased when it is combined with Vitamin D. |
| 1alpha-Hydroxyvitamin D5 | The serum concentration of Hydrotalcite can be increased when it is combined with 1alpha-Hydroxyvitamin D5. |
| Previtamin D(3) | The serum concentration of Hydrotalcite can be increased when it is combined with Previtamin D(3). |
| Deferiprone | Hydrotalcite can cause a decrease in the absorption of Deferiprone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Eltrombopag | Hydrotalcite can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Hydrotalcite can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The risk or severity of adverse effects can be increased when Tolevamer is combined with Hydrotalcite. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Hydrotalcite. |
| Captopril | Hydrotalcite can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | The serum concentration of Cefpodoxime can be decreased when it is combined with Hydrotalcite. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Hydrotalcite. |
| Chloroquine | Hydrotalcite can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Elvitegravir | Hydrotalcite can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gabapentin enacarbil | The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Hydrotalcite. |
| Hyoscyamine | Hydrotalcite can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rifampin | Hydrotalcite can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mecamylamine | Hydrotalcite may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
| Memantine | Hydrotalcite may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Penicillamine | Hydrotalcite can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Quinidine | Hydrotalcite may decrease the excretion rate of Quinidine which could result in a higher serum level. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Hydrotalcite. |
| Deferasirox | Hydrotalcite can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Allopurinol | The therapeutic efficacy of Allopurinol can be decreased when used in combination with Hydrotalcite. |
| Dolutegravir | The serum concentration of Dolutegravir can be decreased when it is combined with Hydrotalcite. |
| Fexofenadine | Hydrotalcite can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Hydrotalcite can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Halofantrine | Hydrotalcite can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Misoprostol | The risk or severity of adverse effects can be increased when Hydrotalcite is combined with Misoprostol. |
| Mesalazine | Hydrotalcite can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | The serum concentration of Mycophenolic acid can be decreased when it is combined with Hydrotalcite. |
| Ursodeoxycholic acid | Hydrotalcite can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycochenodeoxycholic Acid | Hydrotalcite can cause a decrease in the absorption of Glycochenodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholic Acid | Hydrotalcite can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycocholic acid | Hydrotalcite can cause a decrease in the absorption of Glycocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deoxycholic acid | Hydrotalcite can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurocholic acid | Hydrotalcite can cause a decrease in the absorption of Taurocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Obeticholic acid | Hydrotalcite can cause a decrease in the absorption of Obeticholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chenodeoxycholic acid | Hydrotalcite can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurochenodeoxycholic acid | Hydrotalcite can cause a decrease in the absorption of Taurochenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tauroursodeoxycholic acid | Hydrotalcite can cause a decrease in the absorption of Tauroursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bamet-UD2 | Hydrotalcite can cause a decrease in the absorption of Bamet-UD2 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| cis-Diamminechlorocholylglycinateplatinum(II) | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Hydrotalcite. |
| Dehydrocholic acid | Hydrotalcite can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hyodeoxycholic Acid | Hydrotalcite can cause a decrease in the absorption of Hyodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aramchol | The serum concentration of Aramchol can be decreased when it is combined with Hydrotalcite. |
| Ox bile extract | The serum concentration of Ox bile extract can be decreased when it is combined with Hydrotalcite. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Hydrotalcite. |
| Ketoconazole | Hydrotalcite can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Moxifloxacin | Hydrotalcite can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Grepafloxacin | Hydrotalcite can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enoxacin | Hydrotalcite can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pefloxacin | Hydrotalcite can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trovafloxacin | Hydrotalcite can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nalidixic acid | Hydrotalcite can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosoxacin | Hydrotalcite can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cinoxacin | Hydrotalcite can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lomefloxacin | Hydrotalcite can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gatifloxacin | Hydrotalcite can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norfloxacin | Hydrotalcite can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levofloxacin | Hydrotalcite can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ofloxacin | Hydrotalcite can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sparfloxacin | Hydrotalcite can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Temafloxacin | Hydrotalcite can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fleroxacin | Hydrotalcite can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Technetium Tc-99m ciprofloxacin | Hydrotalcite can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Garenoxacin | Hydrotalcite can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nemonoxacin | Hydrotalcite can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Flumequine | Hydrotalcite can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enrofloxacin | Hydrotalcite can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Orbifloxacin | Hydrotalcite can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarafloxacin | Hydrotalcite can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |